Aquestive Therapeutics Inc (AQST)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Daniel Barber
Employees:
160
30 TECHNOLOGY DRIVE, WARREN, NJ 07059
908-941-1900

Aquestive Therapeutics, Inc. focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formant of buprenorphine and naloxone for the. treatment of opioid dependence.

Data derived from most recent annual or quarterly report
Market Cap 83.884 Million Shares Outstanding55.922 Million Avg 30-day Volume 254.24 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.36
Price to Revenue2.0342 Debt to Equity-0.3672 EBITDA-26.552 Million
Price to Book Value0.0 Operating Margin-61.00600000000001 Enterprise Value111.356 Million
Current Ratio1.029 EPS Growth0.76 Quick Ratio0.842
1 Yr BETA 0.8061 52-week High/Low 2.69 / 0.72 Profit Margin-48.6071
Operating Cash Flow Growth131.868 Free Cash Flow to Firm (FCFF) TTM 9.577 Million Free Cash Flow to Equity (FCFE) TTM-6.017 Million
Altman Z-Score-8.0447
Earnings Report2023-10-31
View SEC Filings from AQST instead.

View recent insider trading info

Aquestive Therapeutics Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding AQST (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding AQST

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-08-09 by BRAENDER LORI J
  • 4: filed on 2023-08-09 by BARBER DANIEL
  • 4: filed on 2023-08-09 by MARSHALL KEN W.
  • 4: filed on 2023-08-09 by BOYD PETER E.
  • 4: filed on 2023-08-09 by KRAUS CARL N
  • 4: filed on 2023-08-09 by WARGACKI STEPHEN
  • 4: filed on 2023-08-09 by SCHOBEL ALEXANDER MARK
  • 4: filed on 2023-08-09 by JUNG CASSIE
  • 3: filed on 2023-06-30 by KRAUS CARL N
  • 4: filed on 2023-06-23 by KROP JULIE

    • Events (8k)

  • 8-K: filed on 2023-09-20:
    Item 8.01: Other Events
  • 8-K: filed on 2023-08-11:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-08-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-08-02:
    Item 1.01: Entry into a Material Definitive Agreement
  • 8-K: filed on 2023-07-27:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-06-29:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-23:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2023-05-31:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-02:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-04-13:
    Item 8.01: Other Events

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    TOTH A ERNEST JR SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-08-09 4

    SCHOBEL ALEXANDER MARK CHIEF INNOVATION/TECH OFFICER

    • Officer
    		 0 2023-08-09 4

    BOYD PETER E. SEE REMARK

    • Officer
    		 0 2023-08-09 4

    MARSHALL KEN W. SVP, CHIEF COMMERCIAL OFFICER

    • Officer
    		 0 2023-08-09 4

    BARBER DANIEL PRESIDENT AND CEO

    • Officer
    		 0 2023-08-09 3

    BRAENDER LORI J SVP, GENERAL COUNSEL

    • Officer
    		 0 2023-08-09 4

    KRAUS CARL N CHIEF MEDICAL OFFICER

    • Officer
    		 150,000 2023-08-09 2

    JUNG CASSIE SVP, OPERATIONS

    • Officer
    		 0 2023-08-09 4

    WARGACKI STEPHEN SVP, RESEARCH & DEVELOPMENT

    • Officer
    		 0 2023-08-09 4

    COSTA SANTO J

    • Director
    		 17,327 2023-06-21 1

    MORRIS TIMOTHY E

    • Director
    		 0 2023-06-21 1

    BROWN GREGORY B

    • Director
    		 75,085 2023-06-21 1

    COCHRAN JOHN

    • Director
    		 99,486 2023-06-21 1

    TAGLIETTI MARCO

    • Director
    		 0 2023-06-21 1

    KROP JULIE

    • Director
    		 0 2023-06-21 1

    TRUITT KENNETH CHIEF MEDICAL OFFICER

    • Officer
    		 100,000 2022-09-06 0

    KENDALL KEITH J CEO AND PRESIDENT

    • Officer
    • Director
    		 1,012,149 2022-03-10 0

    WOOD THERESA SVP-HR AND ORG. DEVELOPMENT

    • Officer
    		 150,765 2022-03-10 0

    SCIBETTA JAMES S

    • Director
    		 51,635 2021-06-15 0

    LURKER NANCY

    • Director
    		 20,000 2021-06-15 0

    BRATTON DOUGLAS K

    MONOLINE PARTNERS, L.P.

    MONOLINE RX, L.P.

    MONOLINE RX II, L.P.

    MONOLINE RX III, L.P.

    MONOSOL RX GENPAR, L.P.

    MRX PARTNERS, LLC

    BRATTON CAPITAL INC.

    BRATTON CAPITAL MANAGEMENT, L.P.

    • 10% Owner
    		 9,823,543 2021-03-12 0

    MAXWELL JOHN T. SVP-CHIEF FINANCIAL OFFICER

    • Officer
    		 150,614 2020-08-18 0

    BRATTON DOUGLAS K

    • Director
    • 10% Owner
    		 11,578,379 2020-06-16 0

    SLATKO GARY H SVP, CHIEF MEDICAL OFFICER

    • Officer
    		 50,000 2020-03-16 0

    BRATTON DOUGLAS K

    MRX PARTNERS, LLC

    MONOLINE RX, L.P.

    MONOLINE RX II, L.P.

    MONOLINE RX III, L.P.

    MONOSOL RX GENPAR, L.P.

    • Director
    • 10% Owner
    		 11,413,379 2018-07-24 0

    BRATTON DOUGLAS K

    MONOLINE PARTNERS, L.P.

    BRATTON CAPITAL MANAGEMENT, L.P.

    BRATTON CAPITAL INC.

    • Director
    • 10% Owner
    		 327,540 2018-07-24 0

    MONOLINE PARTNERS, L.P.

    • 10% Owner
    		 165,000 2018-07-24 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    BRAENDER LORI J - Officer SVP, GENERAL COUNSEL

    		2023-08-09 16:30:34 -0400 2023-08-09 A 75,000 a 75,000 direct

    BARBER DANIEL - Officer PRESIDENT AND CEO

    		2023-08-09 16:30:33 -0400 2023-08-09 A 223,500 a 223,500 direct

    MARSHALL KEN W. - Officer SVP, CHIEF COMMERCIAL OFFICER

    		2023-08-09 16:30:32 -0400 2023-08-09 A 75,000 a 75,000 direct

    BOYD PETER E. - Officer SEE REMARK

    		2023-08-09 16:30:32 -0400 2023-08-09 A 50,000 a 50,000 direct

    WARGACKI STEPHEN - Officer SVP, RESEARCH & DEVELOPMENT

    		2023-08-09 16:30:29 -0400 2023-08-09 A 67,500 a 67,500 direct

    TOTH A ERNEST JR - Officer SVP, CHIEF FINANCIAL OFFICER

    		2023-08-09 16:30:26 -0400 2023-08-09 A 70,000 a 70,000 direct

    SCHOBEL ALEXANDER MARK - Officer CHIEF INNOVATION/TECH OFFICER

    		2023-08-09 16:30:22 -0400 2023-08-09 A 50,000 a 50,000 direct

    JUNG CASSIE - Officer SVP, OPERATIONS

    		2023-08-09 16:30:17 -0400 2023-08-09 A 55,000 a 55,000 direct

    KRAUS CARL N - Officer CHIEF MEDICAL OFFICER

    		2023-08-09 16:30:31 -0400 2023-08-09 A 150,000 a 150,000 direct -0.5128 -10.7692 -18.9744 0.0 1 -23.0769 21

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 22:15:03 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 21:45:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 21:15:03 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 20:45:05 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 20:15:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 19:45:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 19:15:03 UTC 0.0 0.0 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 18:45:03 UTC 0.0 0.0 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 18:15:03 UTC 0.0 0.0 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 17:45:03 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 17:15:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 16:45:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 16:15:03 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 15:45:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 15:15:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 14:45:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 14:15:04 UTC 0.7339 4.5861 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 13:45:03 UTC 0.5788 4.7412 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 13:15:04 UTC 0.5788 4.7412 2700000
    AQUESTIVE THERAPEUTICS INC AQST 2023-09-29 12:45:05 UTC 0.5788 4.7412 2700000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund AQST -4100.0 shares, $-6765.0 2023-06-30 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments